The trial was conducted between October 2022 and July 2023 and enrolled 144 homebound older adults who required hospital-level treatment for acute infections. Rather than a single medical center, the study spanned five hospitals and thirteen community clinics across Taiwan, reflecting a deliberate effort to test the model within the country’s existing Integrated Home-Based Medical Care system rather than in a purpose-built research environment. Participants were randomly allocated in a non-randomized controlled design: 83 received hospital-at-home care, while 61 received standard inpatient care in a brick-and-mortar hospital. The researchers were careful to note that this was a pilot study, designed to generate the preliminary evidence needed before Taiwan scales the model nationally.

The population studied is precisely the group for whom hospitalization carries the greatest hazards. Participants were generally frail, chronically ill, and functionally dependent, meaning they were homebound even before they became acutely unwell. For such patients, a trip to the emergency department can trigger a cascade of harms: delirium from the unfamiliar environment, falls, pressure injuries, loss of muscle mass from bed rest, exposure to multidrug-resistant organisms, and the disorientation of being cared for by rotating teams of strangers. Hospital-at-home models, which have been pioneered in the United States, Israel, Australia, and elsewhere, aim to deliver the clinical intensity of a ward while sparing patients these collateral damages.

The Taiwanese model centered on direct home admission is distinctive because most patients were admitted straight from the community, identified by the family physicians and home-care nurses who already knew them, rather than being triaged through an emergency department. A small proportion did enter through an emergency department pathway that cleared them for home treatment. Once enrolled, patients in the hospital-at-home group received a package of interventions that mirrors what a medical ward provides: interprofessional visits from physicians and nurses, intravenous pharmacotherapy administered at the bedside, point-of-care diagnostics such as blood tests performed on site, and remote patient monitoring to track vital signs between visits. The control group received conventional inpatient care.

The primary outcomes focused on the questions any clinician would ask before sending a frail patient home with an intravenous line. Could the illness be resolved without hospital transfer? Would patients deteriorate and need rescue? Would they die during the treatment episode or within 30 days? The answers were reassuring. Remission or complete treatment was achieved in 86.7 percent of the hospital-at-home group compared with 95.1 percent of the hospitalized group, a difference that was not statistically significant. Death during the treatment episode was rare in both arms, at 2.4 percent versus 3.3 percent. Nine of the 83 hospital-at-home patients, or 10.8 percent, required clinical escalation to a hospital, a figure the researchers viewed as an expected safety valve rather than a failure of the model.

Where the home model clearly outperformed the ward was in efficiency and experience. The hospital-at-home group had a significantly shorter length of stay, averaging 9.72 days compared with 11.85 days for conventional inpatients, a difference that reached statistical significance. Shorter treatment episodes matter for more than convenience: they free up scarce hospital beds, reduce the exposure of immunocompromised patients to hospital-acquired pathogens, and lower the cumulative cost of an episode of care. In a health system like Taiwan’s, where an aging population is straining inpatient capacity, shaving two days off the average admission for this population could translate into substantial system-level relief.

The patient experience data were equally striking. Patients and caregivers in the home group reported significantly higher satisfaction and convenience, and significantly greater willingness to choose the model again, compared with those treated in hospitals. This finding aligns with a consistent pattern in the international literature. Qualitative evaluations of hospital-at-home programs elsewhere have found that patients value sleeping in their own beds, eating their own food, and having family nearby without visiting-hour restrictions, while caregivers appreciate being integrated into the care team rather than relegated to visitors. For functionally dependent older adults, avoiding the transfer to an unfamiliar ward may also protect cognition and preserve the routines that anchor daily life.

The technological backbone of the model deserves attention, because it is what makes ward-level care in a living room clinically credible. Intravenous antibiotics and fluids, historically the defining feature of inpatient care, can now be administered safely at home by visiting nurses with standardized protocols. Point-of-care laboratory diagnostics allow clinicians to monitor inflammatory markers, renal function, and other parameters without transporting the patient. Remote patient monitoring devices stream vital signs to the clinical team, enabling early detection of deterioration. Together, these tools compress the distance between the patient and the hospital to the length of a data connection, while the interprofessional home visits preserve the hands-on assessment that remote care alone cannot provide.

The study’s design has limitations that the authors themselves acknowledge. It was a non-randomized pilot, so patients were not assigned by chance, and unmeasured differences between the groups could have influenced the outcomes. The sample size of 144 was sufficient to detect large signals but not subtle ones, and the confidence intervals around the mortality and remission comparisons are correspondingly wide. Selection is also a consideration: only patients judged suitable for home treatment by their clinicians were offered the model, so the results apply to a carefully screened population rather than to all acutely ill older adults. Still, the trial adhered to the CONSORT extension for non-randomized studies, was approved by an institutional review board, and obtained written informed consent from all participants or their legal representatives, lending rigor to what is explicitly a proof-of-concept exercise.

What makes the Taiwanese trial consequential is its policy trajectory. The findings directly informed the development of a national acute care at home program, meaning this was not an academic curiosity but the evidence base for a system-wide rollout. Taiwan is unusually well positioned for such a model because of its mature home-based medical care infrastructure, in which community clinics and home-care nursing agencies already deliver longitudinal care to homebound patients. The direct home admission pathway leverages that existing network: the clinician who knows the patient best becomes the admission gateway, and the home-care team becomes the ward staff. If the national program performs as the pilot suggests, Taiwan will join a small group of health systems, including the United States under its Medicare Acute Hospital Care at Home program, that have moved hospital-at-home from experiment to standard option. For the growing number of countries confronting aging populations and hospital capacity crises, the message from this trial is provocative and practical: for a substantial share of frail older patients, the safest hospital bed may be the one they already sleep in.

Subject of Research: Hospital-at-home acute care via direct home admission for frail older adults in Taiwan

Article Title: Hospital-Level Acute Care at Home via Direct Home Admission in Taiwan: A Non-randomized Controlled Pilot Trial Before National Implementation

Article References: Wang, Y.-C., Liao, J.-Y., Yang, F.-C., Huang, S.-W., Tseng, W.-Z., Chang, H.-C., Huang, C.-H., Yu, S.-J., Chen, Y.-C., Huang, T.-H., Chen, H.-Y., Lin, C.-C. C., & Chen, P.-J. (2026). Hospital-Level Acute Care at Home via Direct Home Admission in Taiwan: A Non-randomized Controlled Pilot Trial Before National Implementation. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10828-2

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10828-2

Keywords: hospital-at-home, direct home admission, acute care at home, frail older adults, home-based medical care, Taiwan, pilot trial, remote patient monitoring, geriatrics, health policy, patient satisfaction, length of stay

The study, led by Julia Browne of the Wellness and Recovery After Psychosis Program at Boston Medical Center Health System and colleagues at Boston University, Massachusetts General Hospital, and Harvard Medical School, enrolled nineteen adults with schizophrenia in a two-period randomized cross-over pilot trial. Participants were assigned to either an intervention phase or a control phase for the first eleven weeks, then crossed over for the second eleven-week period. The intervention consisted of virtually delivered lifestyle programming built around structured exercise sessions and nutrition education, designed to be accessible from home — a delivery model motivated by the well-documented barriers that keep people with serious mental illness out of traditional in-person programs, including transportation difficulties, social anxiety, stigma, scheduling conflicts, and the fatigue and motivational deficits that often accompany psychotic disorders.

The rationale for targeting physical health in this population is unambiguous in the epidemiological literature. Meta-analyses have consistently shown that cardiovascular disease is the leading cause of death among people with schizophrenia, with prevalence and incidence rates far exceeding those of matched controls. Large-scale studies of first-episode psychosis already reveal elevated cardiometabolic risk at the very beginning of treatment, and national register studies have documented increased cardiovascular mortality persisting across decades. People with psychosis are also among the most sedentary groups studied anywhere in medicine, and their diets tend to be poorer in quality than those of the general population. Lifestyle interventions — behavioral weight-loss programs, health promotion coaching, and structured exercise — have repeatedly demonstrated effectiveness in controlled settings, which makes the real question one of implementation: how do you get people to participate, and stay participating, in programs that demand sustained behavioral change from a population facing cognitive, motivational, and logistical obstacles?

On the feasibility side, the pilot’s numbers tell a nuanced story. During the first eleven-week period, retention was 58 percent and intervention engagement reached 67 percent — modest figures, but not dramatically out of line with what has been reported for physical activity interventions in schizophrenia generally, where dropout is a persistent and well-documented problem. During the second period, however, the picture deteriorated sharply. Retention fell to 37 percent and intervention engagement to 50 percent, rates low enough that the investigators were forced to abandon their planned cross-over analysis entirely. With so few participants contributing data in the second half of the study, neither a formal cross-over comparison nor an examination of outcome changes during that period was statistically possible. The attrition itself became one of the study’s most important findings.

The secondary outcomes, analyzed for the first period only, were considerably more encouraging. Comparing changes between the intervention and control groups across weeks one through eleven, the researchers found effects favoring the intervention across a striking range of measures: nutritional knowledge, physical activity levels, mental health, physical health, exercise motivation, self-esteem, and weight and body mass index. The standardized effect sizes, expressed as Cohen’s d values, ranged from 0.35 to 2.09 — a spread that runs from modest to very large by conventional standards. While the small sample and sparse data mean these estimates carry wide uncertainty and cannot be treated as definitive evidence of efficacy, the breadth and direction of the changes suggest that the intervention content itself, when participants actually engaged with it, was doing something meaningful across multiple domains of health and wellbeing simultaneously.

Satisfaction data, though available for only six participants, added a further note of optimism. Nearly all of those who completed the satisfaction assessment reported that the intervention was helpful and easy to follow. For a virtual format targeting a population that is often assumed to struggle with technology-mediated care, that acceptability signal matters. It aligns with a growing body of work from the same research group and others showing that people with serious mental illness are willing and often eager to use remote health tools, including virtual walking groups and mobile-health-supported peer programs, provided the content is designed with their needs in mind.

Why did engagement collapse in the second period? The authors point to attrition and the sparsity of data as the proximate obstacles to analysis, but the pattern itself raises questions that the pilot was not powered to answer definitively. Cross-over designs are elegant on paper — every participant serves as their own control, reducing between-person variability and requiring smaller samples — but they impose a double burden: participants must commit to a program lasting more than four months, and those assigned to control first must sustain engagement through a waiting period before receiving anything of perceived value. For people managing a chronic psychotic illness, with its attendant motivational challenges and symptom fluctuations, that structural demand may itself have driven the steep second-period losses. The study’s design, in other words, may have been as much a test of endurance as of the intervention.

The authors are explicit about the implication: intervention development research is needed to determine whether modifications to this virtual lifestyle intervention would enhance feasibility and acceptability for people with schizophrenia. That is the language of honest pilot science — the study was designed to generate lessons, not conclusions, and the lessons here are twofold. First, the content works well enough for those who stay engaged to produce measurable improvements in knowledge, behavior, mood, self-esteem, and weight. Second, the delivery model, or the study structure wrapped around it, loses people at rates that would undermine any real-world deployment. Candidate refinements might include shorter program durations, intensified early engagement strategies, simplified technology, peer support integration, or hybrid models that pair virtual sessions with periodic in-person contact — each of which has precedent in the broader lifestyle intervention literature for serious mental illness.

The stakes of solving this problem are difficult to overstate. The longevity gap between people with schizophrenia and the general population has been widening rather than narrowing in recent decades, a trend documented across multiple countries and health systems. Pharmacological and non-pharmacological interventions to improve physical health in this population are supported by an increasingly robust evidence base, including meta-reviews of hundreds of randomized trials. What remains scarce are delivery models that survive contact with the realities of patients’ lives. This pilot does not settle whether virtual delivery can be that model, but by pairing encouraging satisfaction and outcome signals with unflinching retention data, it gives the field something arguably more valuable than a positive result: a precise map of where the approach breaks down, and a foundation on which the next iteration can be built. For a population whose lives literally depend on accessible, sustainable health programs, that map is a contribution worth taking seriously.

Subject of Research: A pilot feasibility study of a virtual exercise and nutrition lifestyle intervention for adults with schizophrenia.

Article Title: A Pilot Feasibility Study of a Virtual Lifestyle Intervention for Individuals with Schizophrenia

Article References: Browne, J., Gouse, B. M., Weinberg, J., Blanton, A., Simons, G., Thomas, O., Camacho, L., LeFeber, L., Agarwal, N., Donovan, A. L., Cather, C., & Brown, H. E. (2026). A Pilot Feasibility Study of a Virtual Lifestyle Intervention for Individuals with Schizophrenia. Community Mental Health Journal. https://doi.org/10.1007/s10597-026-01722-6

Image Credits: AI Generated

DOI: 10.1007/s10597-026-01722-6

Keywords: schizophrenia, virtual lifestyle intervention, telehealth, exercise, nutrition, cardiometabolic health, psychosis, feasibility study, mental illness, physical activity, retention, pilot trial

Huntington’s disease is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene, which produces a toxic mutant protein that progressively destroys neurons, particularly in the striatum and cortex. Symptoms typically emerge in midlife and include involuntary choreiform movements, cognitive decline, psychiatric disturbance, and profound metabolic abnormalities. Patients commonly experience unintended weight loss, altered glucose metabolism, mitochondrial dysfunction, and disrupted circadian rhythms—features that worsen as the disease advances and that strongly predict clinical progression. Body weight, in fact, is a robust predictor of how quickly the disease moves, and metabolic disturbances have been documented in the muscle, fibroblasts, and brains of affected individuals for decades. Despite an intense global research effort, including recent phase 3 trials of pridopidine and the antisense oligonucleotide tominersen, no therapy has yet been shown to decisively alter the disease course.

It is precisely this metabolic signature that made time-restricted eating an attractive candidate. In preclinical work, dietary restriction and intermittent fasting normalized glucose metabolism, elevated brain-derived neurotrophic factor, slowed disease progression, and extended survival in mutant huntingtin mice. Time-restricted feeding improved circadian dysfunction and motor symptoms in the Q175 mouse model, and circadian-based treatment strategies proved effective in the BACHD mouse model. Mechanistically, researchers believe the benefits stem from intermittent metabolic switching: the periodic transition from glucose-based fuel to ketone bodies and fatty acid oxidation that occurs during fasting windows. This metabolic switch triggers a cascade of adaptive responses, including enhanced autophagy—the cellular housekeeping process that clears damaged proteins, including mutant huntingtin aggregates—alongside improved mitochondrial function, reduced inflammation, and changes in circulating factors such as growth hormone, ghrelin signaling modulators like LEAP2, FGF21, and bile acids. The gut microbiota may also mediate some of the cognitive benefits observed with intermittent fasting in animal studies.

The new trial, registered as NCT06490367, enrolled 20 individuals with early-stage manifest Huntington’s disease in a 12-week open-label pilot study. Participants were asked to consume all of their daily calories within an eight-hour window, alongside standard-of-care diet and activity recommendations. The design deliberately avoided calorie counting or prescribed diets, isolating the timing of eating as the sole variable. Adherence was tracked through self-reported daily eating intervals and corroborated with time-stamped smartphone application data, which showed strong agreement between the two measures. Participants successfully compressed their eating windows from baseline habits, shifting the timing of both first and last caloric intake without substantially altering sleep onset or wake times—a critical point, since the intervention appeared to act on meal timing rather than simply disrupting sleep patterns.

The results were encouraging on multiple fronts. First, the intervention proved feasible: participants sustained the eight-hour eating window across the trial period with adherence rates indicating that most days met the protocol definition. Second, the regimen was well tolerated, an important consideration in a population at risk of weight loss, where aggressive caloric restriction could be harmful. Notably, the trial paired time-restricted eating with standard nutritional guidance precisely to guard against unintended weight decline. Third, and most strikingly, the researchers observed favorable changes in clinical measures of Huntington’s disease, including components of the composite Unified Huntington’s Disease Rating Scale, a validated outcome measure designed to capture clinically meaningful change in early-stage patients. In a disease defined by steady deterioration, even short-term stability or improvement on such measures in a small uncontrolled trial is noteworthy, though the authors and outside experts alike caution that practice effects and the absence of a control group make it impossible to attribute the changes confidently to the intervention.

Perhaps the most provocative finding concerned plasma neurofilament light chain, a protein released when neurons are injured that has emerged as one of the most reliable fluid biomarkers of neurodegeneration. Five-year longitudinal analyses have shown that plasma neurofilament light tracks neurodegeneration across the Huntington’s disease spectrum, and it is increasingly used as a secondary endpoint in therapeutic trials. In this pilot, levels of the biomarker moved in a favorable direction over the 12-week intervention, hinting—tentatively—that time-restricted eating might influence the very process of neuronal injury. The researchers also examined peripheral mitochondrial bioenergetics by measuring oxygen consumption rates in peripheral blood mononuclear cells using a mitochondrial stress test protocol, assessing basal respiration, ATP-linked respiration, maximal respiration, and spare respiratory capacity before and after the intervention. Given the well-documented mitochondrial dysfunction in Huntington’s disease, including transcriptional repression of PGC-1α by mutant huntingtin, these cellular energy measurements provide a mechanistic window into how a dietary intervention might interact with the disease’s underlying bioenergetic deficits.

The trial also monitored a broad panel of secondary outcomes reflecting the metabolic and inflammatory dimensions of the disease. Researchers assessed body composition, sleep quality using the Pittsburgh Sleep Quality Index, cognition with the Montreal Cognitive Assessment, and dietary quality using tools including the dietary inflammatory index and a Mediterranean diet score—an important control, since pro-inflammatory dietary patterns have been linked to dementia incidence in population studies. This comprehensive phenotyping reflects a deliberate strategy: rather than betting on a single endpoint, the pilot was designed to map the full physiological footprint of time-restricted eating in this population, generating hypotheses and effect-size estimates to power larger controlled trials. All source data from the study have been made publicly available through a Mendeley Data repository, and the trial protocol itself was published in advance in PLoS ONE, exemplifying the transparent, staged approach increasingly favored for lifestyle intervention research.

Experts in the field emphasize both the promise and the limitations of the work. As an open-label study without a placebo group, the trial cannot exclude expectation effects, regression to the mean, or practice effects on repeated neuropsychological testing, phenomena that are well documented in Huntington’s disease cohorts and even proposed as dynamic biomarkers of early cognitive change. The sample of 20 participants, while adequate for establishing feasibility, is far too small to detect the modest treatment effects that have frustrated large pharmaceutical trials. The history of Huntington’s disease research is littered with interventions that looked promising in early-phase studies—often with biomarker signals similar to those reported here—only to fail in definitive testing. Modeling work drawing on the Enroll-HD and GENERATION HD1 cohorts has highlighted how difficult it is to distinguish true disease modification from placebo response and natural variability in progression rates.

Nevertheless, the study represents a genuine milestone: the first time a fasting-based intervention has been formally tested in people with Huntington’s disease, translating nearly two decades of preclinical evidence into the clinic. If larger randomized controlled trials confirm that simply restricting the daily eating window can stabilize clinical measures and favorably shift neurodegeneration biomarkers, the implications would extend far beyond this single rare disease. Time-restricted eating is inexpensive, scalable, and already practiced by millions worldwide for weight management and metabolic health. A rigorous demonstration of neuroprotective effects would position meal timing as a genuine therapeutic modality for the brain. For now, the researchers urge restraint: the findings support the need for further investigation, not immediate clinical recommendations. But for a community that has endured decades of therapeutic disappointment, the idea that the clock, as much as the kitchen, might shape the course of Huntington’s disease is a source of hard-won and carefully qualified hope.

Subject of Research: Time-restricted eating as a lifestyle intervention in early-stage Huntington's disease

Article Title: Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study

Article References: Wells, R. G., Neilson, L. E., McHill, A. W., Gray, N. E., Quinn, J. F., & Hiller, A. L. (2026). Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study. Nature Metabolism. https://doi.org/10.1038/s42255-026-01612-x

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01612-x

Keywords: Huntington's disease, time-restricted eating, intermittent fasting, neurodegeneration, neurofilament light, mitochondrial dysfunction, circadian rhythms, autophagy, pilot trial, metabolism, biomarkers, lifestyle intervention